New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
18:47 EDTVRNT, FIVE, RLD, HALO, AXAS, PVH, NVAX, TSLOn The Fly: After Hours Movers
UP AFTER EARNINGS: Verint Systems (VRNT), up 6.78% after reporting better than expected first quarter results and raising fiscal 2015 guidance... Five Below (FIVE), up 2.87% after reporting quarterly results... RealD (RLD), up 1.7%. ALSO HIGHER: Halozyme Therapeutics (HALO), up 13.24% after the FDA removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial... Abraxas Petroleum (AXAS), up 6.67% after raising its fiscal 2014 production guidance to 5,500-5,700 Boepd. DOWN AFTER EARNINGS: PVH Corp. (PVH), down 6.26% after lowering fiscal 2014 guidance... ALSO LOWER: Novavax (NVAX), down 8.66% after filing to sell $100M of common stock... Trina Solar (TSL), down 3.79%.
News For VRNT;FIVE;RLD;HALO;AXAS;PVH;NVAX;TSL From The Last 14 Days
Check below for free stories on VRNT;FIVE;RLD;HALO;AXAS;PVH;NVAX;TSL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 11, 2014
08:55 EDTFIVEFive Below results solid, says Wedbush
Subscribe for More Information
September 10, 2014
18:33 EDTFIVEOn The Fly: After Hours Movers
Subscribe for More Information
16:17 EDTFIVEFive Below drops after results, levels to watch
Subscribe for More Information
16:13 EDTFIVEFive Below down 6% following Q2 results, guidance
16:11 EDTFIVEFive Below opened 30 new stores in Q2
Subscribe for More Information
16:08 EDTFIVEFive Below reports Q2 comparable store sales up 3.2%
Subscribe for More Information
16:08 EDTFIVEFive Below raises FY14 adjusted EPS view to 87c-90c from 86c-89c, consensus 90c
Raises FY14 revenue view to $681M-$687M from $675M-$681M, consensus $684.77M. Guidance based on opening 62 new stores for the full year and assuming a 4% increase in comparable store sales.
16:05 EDTFIVEFive Below sees Q3 EPS 5c-6c, consensus 7c
Sees Q3 revenue $136M-$138M, consensus $136.95M.
16:04 EDTFIVEFive Below reports Q2 EPS 15c, consensus 14c
Reports Q2 revenue $152.5M, consensus $152.24M.
15:50 EDTFIVENotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Restoration Hardware (RH), consensus 64c; Men's Wearhouse (MW), consensus $1.06; Five Below (FIVE), consensus 14c; Sigma Designs (SIGM), consensus (8c); Wet Seal (WTSL), consensus (9c).
12:55 EDTFIVEFive Below September 40 straddle priced for 11.1% move into Q2
11:22 EDTPVHOptions with decreasing implied volatility
Subscribe for More Information
07:05 EDTTSLTrina Solar to supply 70MW high efficiency modules to project in Chile
Subscribe for More Information
07:05 EDTPVHPVH Corp.removed from U.S. Focus List at Credit Suisse
September 9, 2014
16:19 EDTFIVEFive Below signs lease for new distribution center in Southern New Jersey
Subscribe for More Information
12:02 EDTPVHOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CIEN FNSR PAY BKS PVH NAV BYI FTR JOY
07:12 EDTAXASEuro Pacific to hold a conference
Subscribe for More Information
September 8, 2014
11:16 EDTAXASAbraxas Petroleum sees Q3 total production 6,500-6,700 boepd
Sees FY14 total production 5,800-6,000 boepd. Sees Q3 CapEx $56M, FY14 CapEx $190M. Comments from slides that will be presented at the EuroPac conference.
10:42 EDTPVHOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CONN CIEN INSM FNSR PAY PVH SWY
September 7, 2014
12:31 EDTNVAXNovavax presents data on RSV F nanoparticle vaccine induced monoclonal antibody
Novavax presented preclinical data demonstrating that antibodies generated to its RSV F-protein nanoparticle vaccine candidate bind to the site II epitope of the RSV F-protein with a higher affinity than palivizumab, Syangis, at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, in Washington, DC. In poster session 024: I-314b titled "Development and Characterization of Recombinant RSV Nanoparticle Vaccine Induced Monoclonal Antibody.", Novavax used its RSV F vaccine to generate a murine monoclonal antibody, NVX4C6, that binds to the antigenic site II on the RSV F-protein. Using Surface Plasmon Resonance, Novavax was able to compare the binding affinity of NVX4C6 and palivizumab to the antigenic site II. This experiment demonstrated that Novavax' RSV F vaccine can induce antibodies to the antigenic site II that have a higher binding affinity to the site than palivizumab. In addition, NVX4C6 was shown to have a slightly different specificity to the site II epitope and to recognize mutated site II peptide not recognized by palivizumab, suggesting that NVX4C6 may neutralize palivizumab escape mutants.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use